Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinrAIR-Sclrodermie study

被引:140
作者
Hachulla, Eric [1 ]
Carpentier, Patrick [10 ]
Gressin, Virginie [12 ]
Diot, Elisabeth [13 ]
Allanore, Yannick [9 ]
Sibilia, Jean [11 ]
Launay, David
Mouthon, Luc [9 ]
Jego, Patrick [8 ]
Cabane, Jean [7 ]
de Groote, Pascal [6 ]
Chabrol, Amelie [5 ]
Lazareth, Isabelle [4 ]
Guillevin, Loic [9 ]
Clerson, Pierre [3 ]
Humbert, Marc [2 ]
机构
[1] Univ Lille, Claude Huriez Hosp, Dept Internal Med, Natl Reference Ctr Scleroderma, F-59037 Lille, France
[2] Univ Paris 11, Hop Antoine Beclere, AP HP, Clamart, France
[3] Orgametrie, Roubaix, France
[4] Grp Hosp St Joseph, Serv Med Vasc, Paris, France
[5] Hop Toulouse Purpan, Toulouse, France
[6] Hop Cardiol, F-59037 Lille, France
[7] Hop St Antoine, F-75571 Paris, France
[8] Hop Sud, Rennes, France
[9] Hop Cochin, F-75674 Paris, France
[10] Hop Nord, Grenoble, France
[11] Hop Hautepierre, Strasbourg, France
[12] Actel Pharmaceut France, Paris, France
[13] Hop Bretonneau, Tours, France
关键词
Systemic sclerosis; Survival; Pulmonary arterial hypertension; Pulmonary hypertension; PULMONARY ARTERIAL-HYPERTENSION; SCLERODERMA; CANCER; COHORT;
D O I
10.1093/rheumatology/ken488
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinrAIR-Sclrodermie cohort of patients with SSc without severe pulmonary fibrosis or severe left heart disease at baseline. Methods. At 3-year follow-up, vital status was obtained from investigators or French national death records. Causes of death were classified as SSc-related or otherwise. Data were censored at 37 months, time of death or loss to follow-up, whichever was earlier. Survival was estimated using the KaplanMeier method. Multivariate survival analyses were conducted using the Cox model. Results. In total, 546 patients were followed for a median duration of 37 months, representing 1547 patient-years. At baseline, the majority of patients were female, with lcSSc, mean age 54.9 13.0 years and mean duration of SSc of 8.8 8.1 years. In total, 47 patients died, giving a 3-year survival of 91.1 and cumulative mortality of 3.04 deaths per 100 patient-years; 17 deaths (32.2) resulted from pulmonary arterial hypertension (PAH) and eight (17.1) from cancer. Of the 47 patients with PAH at baseline, 20 died during follow-up, giving a 3-year survival of 56.3. In a multivariate analysis, PAH [hazard ratio (HR) 7.246], age at first symptom (HR 1.052), duration of SSc (HR 1.047 per year) and Rodnan skin score (per one point) (HR 1.045) were associated with increased mortality. Conclusion. This 3-year study observed survival and mortality estimates that were comparable with previous reports. PAH increased the HR for mortality in patients with SSc, justifying yearly echocardiographic screening.
引用
收藏
页码:304 / 308
页数:5
相关论文
共 15 条
[1]   PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA) [J].
不详 .
ARTHRITIS AND RHEUMATISM, 1980, 23 (05) :581-590
[2]  
CLEMENTS PJ, 1993, J RHEUMATOL, V20, P1892
[3]   Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis [J].
de Groote, P. ;
Gressin, V. ;
Hachulla, E. ;
Carpentier, P. ;
Guillevin, L. ;
Kahan, A. ;
Cabane, J. ;
Frances, C. ;
Lamblin, N. ;
Diot, E. ;
Patat, F. ;
Sibilia, J. ;
Petit, H. ;
Cracowski, J-L ;
Clerson, P. ;
Humbert, M. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (01) :31-36
[4]  
Derk CT, 2006, J RHEUMATOL, V33, P1113
[5]   Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1,012 Italian patients [J].
Ferri, C ;
Valentini, G ;
Cozzi, F ;
Sebastiani, M ;
Michelassi, C ;
La Montagna, G ;
Bullo, A ;
Cazzato, M ;
Tirri, E ;
Storino, F ;
Giuggioli, D ;
Cuomo, G ;
Rosada, M ;
Bombardieri, S ;
Todesco, S ;
Tirri, G .
MEDICINE, 2002, 81 (02) :139-153
[6]   Guidelines on diagnosis and treatment of pulmonary arterial hypertension -: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology [J].
Galiè, N ;
Torbicki, A ;
Barst, R ;
Dartevelle, P ;
Haworth, S ;
Higenbottam, T ;
Olschewski, H ;
Peacock, A ;
Pietra, G ;
Rubin, LJ ;
Simonneau, G .
EUROPEAN HEART JOURNAL, 2004, 25 (24) :2243-2278
[7]  
Gibbs JSR, 2001, HEART, V86, pI1
[8]   Pulmonary hypertension as a risk factor for death in patients with sickle cell disease [J].
Gladwin, MT ;
Sachdev, V ;
Jison, ML ;
Shizukuda, Y ;
Plehn, JF ;
Minter, K ;
Brown, B ;
Coles, WA ;
Nichols, JS ;
Ernst, I ;
Hunter, LA ;
Blackwelder, WC ;
Schechter, AN ;
Rodgers, GP ;
Castro, O ;
Ognibene, FP .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (09) :886-895
[9]   Early detection of pulmonary arterial hypertension in systemic sclerosis -: A French nationwide prospective multicenter study [J].
Hachulla, E ;
Gressin, V ;
Guillevin, L ;
Carpentier, P ;
Diot, E ;
Sibilia, J ;
Kahan, A ;
Cabane, J ;
Francès, C ;
Launay, D ;
Mouthon, L ;
Allanore, Y ;
Tiev, KP ;
Clerson, P ;
de Groote, P ;
Humbert, M .
ARTHRITIS AND RHEUMATISM, 2005, 52 (12) :3792-3800
[10]   Risk of cancer in patients with scleroderma: a population based cohort study [J].
Hill, CL ;
Nguyen, AM ;
Roder, D ;
Roberts-Thomson, P .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (08) :728-731